$40 Million

Applied Therapeutics, Inc.

Initial Public Offering

Bookrunner, May 2019

Applied Therapeutics, Inc.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The first molecular target of the Company's product candidates is aldose reductase (AR), an enzyme implicated in multiple diseases. The Company's AR program includes three small molecule AR inhibitors (ARI) for the treatment of diabetic complications, heart disease and a rare pediatric metabolic disease. Applied Therapeutics' most advanced product candidate, AT-001, is a novel ARI with peripheral nerve permeability for the treatment of diabetic cardiomyopathy (DbCM). The Company is also advancing several other ARI clinical candidates including, AT-007 and AT-003, for the treatment of galactosemia and diabetic retinopathy (DR), respectively